What’s New!

NEWS

Establishment of EDBI’s new Growth IPO Fund

Boosting Equity Financing for High-Growth Enterprises
EDBI partners Singapore Fintech Festival and Singapore Week of Innovation and Technology 2021
EDBI is proud to have been a supporting partner of SFF x SWITCH 2021, curating, judging and participating in different panels and having our portfolio companies share on how they are transforming communities.
EDBI partners IMDA for their flagship ATxSummit
EDBI partners IMDA for their flagship ATxSummit

Rigetti Computing introduces world’s first scalable multi-chip quantum processor

Rigetti Computing introduces world’s first scalable multi-chip quantum processor

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

Singapore’s Carro Achieves Unicorn Status, Raises SG$477 Million in Series C Funding Led By SoftBank Vision Fund 2

Singapore's Carro Achieves Unicorn Status, Raises SG$477 Million in Series C Funding Led By SoftBank Vision Fund 2

T32 DENTAL GROUP SECURES STRATEGIC INVESTMENT TO DRIVE EXPANSION AND TRANSFORM THE REGIONAL DENTAL SERVICES ECOSYSTEM

T32 DENTAL GROUP SECURES STRATEGIC INVESTMENT TO DRIVE EXPANSION AND TRANSFORM THE REGIONAL DENTAL SERVICES ECOSYSTEM

THE MOST INNOVATIVE FINTECH COMPANIES IN 2021

THE MOST INNOVATIVE FINTECH COMPANIES IN 2021

WalkMe Announces Launch of Initial Public Offering

SAN FRANCISCO, June 7, 2021 /PRNewswire/ — WalkMe Ltd. (“WalkMe”), a leading provider of digital adoption solutions, today announced the launch of its initial public offering of 9,250,000 of its ordinary shares. The underwriters will have a 30-day option to purchase up to an additional 1,387,500 ordinary shares at the initial public offering price, less underwriting discounts and commissions.

WEFOX CLOSES RECORD SERIES C FUNDING ROUND FOR INSURTECH – US$650m, MARKET VALUE US$3bn

wefox, the Berlin-based digital insurance company has raised a record US$650 million for its Series C funding round led by Target Global, resulting in a post-money valuation of US$3 billion.

Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics

MAY 26, 2021 – SINGAPORE & SAN CARLOS, Calif.–Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.

Esco Lifesciences Closes a Record-Setting US$200M Series A Round Led by Vivo Capital and Novo Holdings

SINGAPORE, May 26, 2021 – Esco Lifesciences (“Esco”, the “Company”) announced today the close of an over-subscribed US$200 million Series A and Crossover round. The financing was led by Vivo Capital and Novo Holdings A/S, with participation from new investors including China Investment Corporation, Singapore-based global investor EDBI, a reputable, long-term institutional investor, and other sophisticated investors.

Hummingbird Bioscience Raises US$125 Million in Series C Financing

SINGAPORE, May 17, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced the close of its US$125 million Series C financing round.